Insmed, Inc. (NASDAQ:INSM – Get Free Report) was the recipient of some unusual options trading activity on Thursday. Investors acquired 7,564 call options on the company. This represents an increase of approximately 85% compared to the average daily volume of 4,092 call options.
Insider Buying and Selling
In other Insmed news, insider Orlov S. Nicole Schaeffer sold 101,100 shares of the stock in a transaction that occurred on Thursday, November 19th. The shares were sold at an average price of $145.26, for a total transaction of $14,685,786.00. Following the sale, the insider directly owned 41,895 shares in the company, valued at $6,085,667.70. This represents a 70.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David R. Brennan sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the transaction, the director directly owned 39,238 shares of the company’s stock, valued at $4,865,512. This represents a 38.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. Ethic Inc. grew its position in Insmed by 109.9% during the third quarter. Ethic Inc. now owns 10,498 shares of the biopharmaceutical company’s stock valued at $1,198,000 after acquiring an additional 5,496 shares during the period. Banco Santander S.A. purchased a new position in shares of Insmed in the 3rd quarter worth about $1,043,000. C WorldWide Group Holding A S raised its holdings in shares of Insmed by 62.1% in the 2nd quarter. C WorldWide Group Holding A S now owns 261,110 shares of the biopharmaceutical company’s stock worth $27,840,000 after purchasing an additional 100,000 shares during the period. Motley Fool Asset Management LLC purchased a new position in shares of Insmed in the 3rd quarter worth about $2,034,000. Finally, Empowered Funds LLC lifted its stake in shares of Insmed by 32.6% in the 1st quarter. Empowered Funds LLC now owns 51,986 shares of the biopharmaceutical company’s stock valued at $8,501,000 after purchasing an additional 12,775 shares in the last quarter.
Analyst Ratings Changes
View Our Latest Research Report on INSM
Insmed Price Performance
Shares of INSM opened at $141.33 on Friday. The firm’s fifty day simple moving average is $111.09 and its 200-day simple moving average is $122.71. Insmed has a twelve month low of $90.39 and a twelve month high of $212.75. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.59 and a current ratio of 2.86.
Insmed (NASDAQ:INSM – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The firm had revenue of $524.43 million for the quarter, compared to analyst estimates of $500.36 million. Insmed had a negative return on equity of 96.38% and a negative net margin of 39.85%. The business’s revenue for the quarter was up 268.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.75) EPS. As a group, equities research analysts expect that Insmed will post -1.86 EPS for the current year.
More Insmed News
These are some of the INSM news items that stood out recently:
- Positive Sentiment: Reports that Sanofi is exploring a potential acquisition drove a strong rally in Insmed shares. One analyst cited in coverage suggested a takeover could value the stock at $170–$210 per share, although no deal has been announced. Insmed shares jump as Sanofi weighs potential takeover
- Neutral Sentiment: An Insmed insider sold 101,100 shares, reducing her stake by about 71%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which may temper concerns that the sale reflects a reaction to recent developments.
- Negative Sentiment: The takeover reports are speculative, and analysts are divided over whether a deal would bring pipeline benefits or create financial strain. The lack of a confirmed offer may contribute to caution and profit-taking after the previous session’s surge. Analysts split on potential Sanofi-Insmed deal
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.
See Also
- Five stocks we like better than Insmed
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
